Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 21,056 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Infant Mortality, Preterm Birth, Low Birth Weight, Neonatal Mortality, Perinatal Mortality
Interventions: Iron (27 mg) - folic acid (600 ug), Multiple micronutrient; Dietary Supplement
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 12 Years to 45 Years · Female only
Enrollment: 44,567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: AML
Interventions: Etoposide, Cytarabine, Lenalidomide, Mitoxantrone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Acute Pancreatitis
Interventions: Dabigatran Etexilate Mesylate, Standard of Care; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Vestibular Hypofunction, Binocular Vision Abnormalities, Reduced Vision
Interventions: StableEyes: Incremental Vestibulo-Ocular Reflex Adaptation (IVA); Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Diabetes
Interventions: BMS-903452, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Miramar, Florida • Austin, Texas

Conditions: Mesothelioma, Peritoneal Mesothelioma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV/AIDS, Sexually Transmitted Diseases
Interventions: Peer Mentor, Website only; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 17 Years to 60 Years · Male only
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 20
States / cities: Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more

Conditions: Dental Plaque, Gingivitis
Interventions: Test Dentifrice, Reference Dentifrice (Colgate Cavity Protection Dentifrice); Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Lipid-Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 44
States / cities: Huntsville, Alabama • Tempe, Arizona • Bell Gardens, California + 39 more

Conditions: Smoking, Homeless Persons
Interventions: Bupropion, Nicotine replacement therapy, Contingency Management; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Migraine
Interventions: Zavegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 94
States / cities: Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 86 more

Conditions: Type 1 Diabetes (T1D), Islet Transplantation
Interventions: Maintenance Immunosuppressive Treatment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 8
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 4 more

Conditions: Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions: Furosemide, Placebo; Drug · Other
Lead sponsor: Melanie Maykin, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Cytal Wound Matrix 1-Layer, Standard of Care (SOC); Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland

Conditions: Myasthenia Gravis
Interventions: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Drug
Lead sponsor: Muscular Dystrophy Association; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anemia
Interventions: Lenalidomide, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Centralia, Illinois • Lebanon, New Hampshire + 4 more

Conditions: Cardiovascular Risk Factor
Interventions: Ketone drink, Placebo drink; Dietary Supplement
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania

Conditions: HIV Infections
Interventions: lopinavir/ritonavir plus maraviroc; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rosacea
Interventions: Doxycycline, Metronidazole, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Santa Monica, California • Coral Gables, Florida • Corbin, Kentucky + 8 more

Conditions: Staphylococcal Infections
Interventions: SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, SA4Ag vaccine high dose, SA3Ag vaccine, Blood sample, Placebo, Colonization swab samples; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 284 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 4 more

Conditions: Parkinson's Disease, Deep Brain Stimulation
Interventions: Deep brain stimulation; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Obstructive Sleep Apnea
Interventions: Web-based Access to CPAP Data, Web-based Access to CPAP Data with Financial Incentive; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Wynnewood, Pennsylvania

Search by objective public record fields.

Antenatal Micronutrient Supplementation and Infant Survival

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

Treating Acute Pancreatitis With Dabigatran, a Pilot Study

Visual Influences on Vestibular Adaptation

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

A Pilot Peer Mentor Intervention That Trains Black Men Who Have Sex With Men (BMSM) to Use and Promote Uptake of HIV/STI Self-Testing to Peers and Sex Partners: STAR Study (Self-Testing at Your Residence)

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

A Study to Investigate the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival Health

Open Label Study of Long Term Safety Evaluation of Alirocumab

Contingency Management for Smoking Cessation in Homeless Smokers

Randomized Trial in Adult Participants With Acute Migraines

Extended Follow-Up After Islet Transplantation in T1D

Furosemide vs. Placebo for Severe Antepartum Hypertension

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

Short Term Ketone Supplementation and Cardiometabolic Health

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

Tandem DBS for Parkinson's Disease: A Pilot Study Utilizing STN/GPi + Hypothalamic Stimulation

Promoting Continuous Positive Airway Pressure (CPAP) Adherence